1. Phylogeny  
Tyrosine‐protein kinase JAK3 is a member of the Janus kinase (JAK) family within the broader tyrosine kinase group. Orthologs of JAK3 are widely distributed among vertebrates, and JAK3 is predominantly conserved within hematopoietic lineages across mammalian species (oshea2009januskinasesin pages 1-2). JAK3 is grouped with JAK1, JAK2, and TYK2 in the non‐receptor tyrosine kinase class, and its evolutionary history indicates that its domain organization and regulatory mechanisms emerged early in kinase signaling evolution (rane2000januskinasescomponents pages 1-2). Comparisons with other JAK family kinases reveal a high degree of conservation in the catalytic regions as well as divergence in regulatory domains, reflecting adaptation to specialized roles in immune functions (notarangelo2001mutationsinsevere pages 1-2, oshea2009januskinasesin pages 1-2).

2. Reaction Catalyzed  
JAK3 catalyzes the transfer of a phosphate group from ATP to the hydroxyl group of tyrosine residues on substrate proteins. In biochemical terms, the reaction can be represented as: ATP + [protein]‐tyrosine → ADP + [protein]‐phosphotyrosine + H⁺ (casimirogarcia2018identificationofcyanamidebased pages 32-33). This phosphorylation event creates binding sites for downstream signaling molecules and is critical for the propagation of cytokine-induced signals (oshea2009januskinasesin pages 1-2).

3. Cofactor Requirements  
The catalytic activity of JAK3 is dependent on the presence of divalent metal ions, with Mg²⁺ acting as an essential cofactor. Mg²⁺ is required for proper ATP binding and positioning within the active site, thereby facilitating the efficient transfer of the phosphate group during substrate phosphorylation (oshea2009januskinasesin pages 1-2, ungureanu2005posttranslationalmodificationsin pages 11-14).

4. Substrate Specificity  
JAK3 exhibits substrate specificity towards tyrosine residues located on the intracellular domains of cytokine receptors, particularly those receptors that share the common gamma (γc) chain. The enzyme phosphorylates specific tyrosine residues on subunits such as IL2Rβ and IL2RG, thereby creating docking sites for STAT proteins that are subsequently phosphorylated (casimirogarcia2018identificationofcyanamidebased pages 32-33). The recognition of substrates by JAK3 is mediated by distinct structural features in its catalytic domain that accommodate the recognition motif present in the receptor tails (oshea2009januskinasesin pages 2-4, forster2016selectivejak3inhibitors pages 7-7).

5. Structure  
JAK3 is organized into seven Janus homology (JH) domains. At the N-terminus, the FERM domain (comprising JH5-JH7) mediates binding to the intracellular region of cytokine receptors and is crucial for receptor association (oshea2009januskinasesin pages 1-2, wilks2008thejakkinases pages 1-1). Adjacent to the FERM domain, the SH2-like domain (typically encompassing JH3-JH4) contributes to interactions with receptor phosphotyrosine motifs, although it does not bind phosphotyrosine in a canonical manner (oshea2009januskinasesin pages 2-4). The central region includes a catalytically inactive pseudokinase domain (JH2) that plays a modulatory role by regulating the activity of the adjacent kinase domain; alterations in this domain can impact overall JAK3 function (vihinen2000molecularmodelingof pages 7-9, ungureanu2005posttranslationalmodificationsin pages 11-14). The C-terminal region houses the active kinase domain (JH1), which adopts a bilobed structure typical of protein kinases, with an N-terminal lobe that binds ATP and a C-terminal lobe that accommodates substrate binding. Key catalytic features include the activation loop, which contains tyrosine residues (for instance, Y980 and Y981) that modulate kinase activity upon phosphorylation, and conserved motifs such as the DFG motif and a gatekeeper residue that contribute to both substrate binding and inhibitor selectivity (casimirogarcia2018identificationofcyanamidebased pages 32-33, wilks2008thejakkinases pages 5-6, forster2017recentadvancesin pages 16-18). Additionally, a unique cysteine residue (Cys909) within the ATP-binding site has been exploited for the development of covalent irreversible or covalent-reversible inhibitors, providing the basis for isoform-selective inhibition (forster2017recentadvancesin pages 18-20, wilks2008thejakkinases pages 9-9).

6. Regulation  
JAK3 regulatory mechanisms involve a combination of intramolecular interactions, post-translational modifications, and extrinsic regulatory proteins. Autophosphorylation of key tyrosine residues within the activation loop (notably Y980 and Y981) is critical for full enzymatic activation, and differential phosphorylation of these sites modulates catalytic output (oshea2009januskinasesin pages 15-16, smith2016essentialbiphasicrole pages 5-6). In addition to autophosphorylation, the pseudokinase domain (JH2) exerts an inhibitory effect on basal kinase activity, ensuring that JAK3 remains inactive in the absence of receptor stimulation (vihinen2000molecularmodelingof pages 5-7, ungureanu2005posttranslationalmodificationsin pages 11-14). Regulatory proteins such as SOCS family members further modulate JAK3 activity by binding to the receptor–kinase complex and promoting ubiquitination and subsequent proteasomal degradation (rane2000januskinasescomponents pages 12-13, oshea2009januskinasesin pages 13-15). In addition, protein tyrosine phosphatases like SHP-1 and CD45 dephosphorylate active JAK3, providing a negative feedback loop that limits the duration of signaling (oshea2009januskinasesin pages 16-17, rane2000januskinasescomponents pages 13-14).

7. Function  
JAK3 plays an essential role in mediating signal transduction downstream of type I cytokine receptors that share the common gamma (γc) chain, including receptors for interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Following ligand binding, receptor dimerization brings JAK3 into proximity with receptor subunits, where it phosphorylates specific tyrosine residues on the cytoplasmic tails of these receptors. These phosphorylated residues serve as docking sites for STAT transcription factors, which are subsequently phosphorylated by JAK3 and/or its partner kinases such as JAK1 (casimirogarcia2018identificationofcyanamidebased pages 32-33, oshea2009januskinasesin pages 16-17). The activated STATs dimerize and translocate to the nucleus, where they contribute to the transcription of genes essential for T-cell development, proliferation, and differentiation. JAK3 is predominantly expressed in hematopoietic cells and is critical for the functional maturation of T cells and natural killer cells, thereby playing a pivotal role in both innate and adaptive immunity (notarangelo2001mutationsinsevere pages 1-2, ndiaye2016differentialregulationof pages 1-2). The signaling cascade mediated by JAK3 thus underpins essential biological processes such as hematopoiesis and immune response regulation.

8. Other Comments  
Selective inhibition of JAK3 has been the focus of extensive medicinal chemistry research due to its restricted expression in immune cells and its central role in cytokine signaling. Inhibitors such as CP-690,550 (tofacitinib) and various cyanamide-based compounds have been developed to target a unique active site residue, Cys909, which confers high isoform selectivity (casimirogarcia2018identificationofcyanamidebased pages 32-33, forster2016selectivejak3inhibitors pages 7-7). Recent advances have introduced both irreversible and covalent-reversible inhibitors that exploit this unique cysteine for selective inhibition of JAK3 over other family members (forster2017recentadvancesin pages 20-23). In addition, mutations in JAK3, particularly those that disrupt its kinase domain or its receptor-binding FERM domain, are associated with severe combined immunodeficiency (SCID), underscoring its critical role in immune regulation (notarangelo2001mutationsinsevere pages 9-9). These inhibitors and mutation studies not only serve as chemical probes for elucidating JAK3 function but also have significant therapeutic implications for autoimmune diseases and transplant rejection (forster2017recentadvancesin pages 16-18, wilks2008thejakkinases pages 9-9).

9. References  
casimirogarcia2018identificationofcyanamidebased pages 32-33  
forster2016selectivejak3inhibitors pages 7-7  
forster2017recentadvancesin pages 9-12  
forster2017recentadvancesin pages 16-18  
forster2017recentadvancesin pages 18-20  
forster2017recentadvancesin pages 20-23  
hall2010expressionpurificationcharacterization pages 1-2  
hall2010expressionpurificationcharacterization pages 8-10  
hall2010expressionpurificationcharacterization pages 10-10  
notarangelo2001mutationsinsevere pages 1-2  
notarangelo2001mutationsinsevere pages 9-9  
oshea2009januskinasesin pages 1-2  
oshea2009januskinasesin pages 2-4  
oshea2009januskinasesin pages 6-8  
oshea2009januskinasesin pages 13-15  
oshea2009januskinasesin pages 15-16  
oshea2009januskinasesin pages 16-17  
oshea2009januskinasesin pages 20-23  
rane2000januskinasescomponents pages 1-2  
rane2000januskinasescomponents pages 10-11  
rane2000januskinasescomponents pages 12-13  
rane2000januskinasescomponents pages 13-14  
rane2000januskinasescomponents pages 2-3  
rane2000januskinasescomponents pages 3-4  
rane2000januskinasescomponents pages 5-7  
smith2016essentialbiphasicrole pages 2-2  
smith2016essentialbiphasicrole pages 5-6  
ungureanu2005posttranslationalmodificationsin pages 9-11  
ungureanu2005posttranslationalmodificationsin pages 11-14  
ungureanu2005posttranslationalmodificationsin pages 14-16  
vihinen2000molecularmodelingof pages 3-5  
vihinen2000molecularmodelingof pages 5-7  
vihinen2000molecularmodelingof pages 7-9  
wilks2008thejakkinases pages 1-1  
wilks2008thejakkinases pages 3-4  
wilks2008thejakkinases pages 4-5  
wilks2008thejakkinases pages 5-6  
wilks2008thejakkinases pages 8-9  
wilks2008thejakkinases pages 9-9  
caveney2023structuralbasisof pages 3-5  
meyer2014molecularpathwaysmolecular pages 1-3  
morris2018themoleculardetails pages 37-39  
ndiaye2016differentialregulationof pages 1-2  
shi2019discoveryofan pages 13-13  
lv2024thejakstatpathway pages 11-12  
lv2024thejakstatpathway pages 12-15

References

1. (casimirogarcia2018identificationofcyanamidebased pages 32-33): Agustin Casimiro-Garcia, John I. Trujillo, Felix Vajdos, Brian Juba, Mary Ellen Banker, Ann Aulabaugh, Paul Balbo, Jonathan Bauman, Jill Chrencik, Jotham W. Coe, Robert Czerwinski, Martin Dowty, John D. Knafels, Soojin Kwon, Louis Leung, Sidney Liang, Ralph P. Robinson, Jean-Baptiste Telliez, Ray Unwalla, Xin Yang, and Atli Thorarensen. Identification of cyanamide-based janus kinase 3 (jak3) covalent inhibitors. Journal of Medicinal Chemistry, 61:10665-10699, Nov 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b01308, doi:10.1021/acs.jmedchem.8b01308. This article has 77 citations and is from a highest quality peer-reviewed journal.

2. (forster2016selectivejak3inhibitors pages 7-7): Michael Forster, Apirat Chaikuad, Silke M. Bauer, Julia Holstein, Matthew B. Robers, Cesear R. Corona, Matthias Gehringer, Ellen Pfaffenrot, Kamran Ghoreschi, Stefan Knapp, and Stefan A. Laufer. Selective jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chemical Biology, 23:1335-1340, Nov 2016. URL: https://doi.org/10.1016/j.chembiol.2016.10.008, doi:10.1016/j.chembiol.2016.10.008. This article has 121 citations and is from a domain leading peer-reviewed journal.

3. (forster2017recentadvancesin pages 9-12): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic &amp; Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.

4. (hall2010expressionpurificationcharacterization pages 1-2): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.

5. (notarangelo2001mutationsinsevere pages 1-2): Luigi D. Notarangelo, Patrizia Mella, Alison Jones, Genevieve de Saint Basile, Gianfranco Savoldi, Treena Cranston, Mauno Vihinen, and Richard Fabian Schumacher. Mutations in severe combined immune deficiency (scid) due to jak3 deficiency. Human Mutation, 18:255-263, Oct 2001. URL: https://doi.org/10.1002/humu.1188, doi:10.1002/humu.1188. This article has 161 citations and is from a domain leading peer-reviewed journal.

6. (oshea2009januskinasesin pages 1-2): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

7. (oshea2009januskinasesin pages 16-17): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

8. (oshea2009januskinasesin pages 2-4): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

9. (smith2016essentialbiphasicrole pages 5-6): Geoffrey A Smith, Kenji Uchida, Arthur Weiss, and Jack Taunton. Essential biphasic role for jak3 catalytic activity in il-2 receptor signaling. Nature Chemical Biology, 12:373-379, Mar 2016. URL: https://doi.org/10.1038/nchembio.2056, doi:10.1038/nchembio.2056. This article has 89 citations and is from a highest quality peer-reviewed journal.

10. (ungureanu2005posttranslationalmodificationsin pages 11-14): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.

11. (vihinen2000molecularmodelingof pages 5-7): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O'Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.

12. (vihinen2000molecularmodelingof pages 7-9): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O'Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.

13. (wilks2008thejakkinases pages 1-1): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

14. (wilks2008thejakkinases pages 5-6): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

15. (caveney2023structuralbasisof pages 3-5): Nathanael A. Caveney, Robert A. Saxton, Deepa Waghray, Caleb R. Glassman, Naotaka Tsutsumi, Stevan R. Hubbard, and K. Christopher Garcia. Structural basis of janus kinase trans-activation. Cell Reports, 42:112201, Mar 2023. URL: https://doi.org/10.1016/j.celrep.2023.112201, doi:10.1016/j.celrep.2023.112201. This article has 35 citations and is from a highest quality peer-reviewed journal.

16. (forster2017recentadvancesin pages 18-20): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic &amp; Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.

17. (hall2010expressionpurificationcharacterization pages 8-10): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.

18. (meyer2014molecularpathwaysmolecular pages 1-3): Sara C. Meyer and Ross L. Levine. Molecular pathways: molecular basis for sensitivity and resistance to jak kinase inhibitors. Clinical Cancer Research, 20:2051-2059, Apr 2014. URL: https://doi.org/10.1158/1078-0432.ccr-13-0279, doi:10.1158/1078-0432.ccr-13-0279. This article has 195 citations and is from a highest quality peer-reviewed journal.

19. (morris2018themoleculardetails pages 37-39): Rhiannon Morris, Nadia J. Kershaw, and Jeffrey J. Babon. The molecular details of cytokine signaling via the jak/stat pathway. Protein Science, 27:1984-2009, Nov 2018. URL: https://doi.org/10.1002/pro.3519, doi:10.1002/pro.3519. This article has 896 citations and is from a peer-reviewed journal.

20. (ndiaye2016differentialregulationof pages 1-2): Kalidou Ndiaye, Amélie Castonguay, Gabriel Benoit, David W. Silversides, and Jacques G. Lussier. Differential regulation of janus kinase 3 (jak3) in bovine preovulatory follicles and identification of jak3 interacting proteins in granulosa cells. Journal of Ovarian Research, Oct 2016. URL: https://doi.org/10.1186/s13048-016-0280-5, doi:10.1186/s13048-016-0280-5. This article has 23 citations and is from a peer-reviewed journal.

21. (notarangelo2001mutationsinsevere pages 9-9): Luigi D. Notarangelo, Patrizia Mella, Alison Jones, Genevieve de Saint Basile, Gianfranco Savoldi, Treena Cranston, Mauno Vihinen, and Richard Fabian Schumacher. Mutations in severe combined immune deficiency (scid) due to jak3 deficiency. Human Mutation, 18:255-263, Oct 2001. URL: https://doi.org/10.1002/humu.1188, doi:10.1002/humu.1188. This article has 161 citations and is from a domain leading peer-reviewed journal.

22. (oshea2009januskinasesin pages 13-15): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

23. (oshea2009januskinasesin pages 15-16): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

24. (oshea2009januskinasesin pages 20-23): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

25. (oshea2009januskinasesin pages 6-8): JJ O'Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.

26. (rane2000januskinasescomponents pages 1-2): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

27. (rane2000januskinasescomponents pages 10-11): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

28. (rane2000januskinasescomponents pages 12-13): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

29. (rane2000januskinasescomponents pages 13-14): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

30. (rane2000januskinasescomponents pages 2-3): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

31. (rane2000januskinasescomponents pages 3-4): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

32. (rane2000januskinasescomponents pages 5-7): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.

33. (shi2019discoveryofan pages 13-13): Liyang Shi, Zhenpeng Zhong, Xitao Li, Yiqing Zhou, and Zhengying Pan. Discovery of an orally available janus kinase 3 selective covalent inhibitor. Journal of Medicinal Chemistry, 62:1054-1066, Jan 2019. URL: https://doi.org/10.1021/acs.jmedchem.8b01823, doi:10.1021/acs.jmedchem.8b01823. This article has 31 citations and is from a highest quality peer-reviewed journal.

34. (smith2016essentialbiphasicrole pages 2-2): Geoffrey A Smith, Kenji Uchida, Arthur Weiss, and Jack Taunton. Essential biphasic role for jak3 catalytic activity in il-2 receptor signaling. Nature Chemical Biology, 12:373-379, Mar 2016. URL: https://doi.org/10.1038/nchembio.2056, doi:10.1038/nchembio.2056. This article has 89 citations and is from a highest quality peer-reviewed journal.

35. (ungureanu2005posttranslationalmodificationsin pages 14-16): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.

36. (ungureanu2005posttranslationalmodificationsin pages 9-11): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.

37. (vihinen2000molecularmodelingof pages 3-5): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O'Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.

38. (wilks2008thejakkinases pages 3-4): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

39. (wilks2008thejakkinases pages 4-5): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

40. (wilks2008thejakkinases pages 8-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

41. (wilks2008thejakkinases pages 9-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell &amp; Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.

42. (forster2017recentadvancesin pages 16-18): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic &amp; Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.

43. (forster2017recentadvancesin pages 20-23): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic &amp; Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.

44. (hall2010expressionpurificationcharacterization pages 10-10): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.

45. (lv2024thejakstatpathway pages 11-12): You Lv, Jianxun Qi, Jeffrey J. Babon, Longxing Cao, Guohuang Fan, Jiajia Lang, Jin Zhang, Pengbing Mi, Bostjan Kobe, and Faming Wang. The jak-stat pathway: from structural biology to cytokine engineering. Signal Transduction and Targeted Therapy, Aug 2024. URL: https://doi.org/10.1038/s41392-024-01934-w, doi:10.1038/s41392-024-01934-w. This article has 28 citations and is from a peer-reviewed journal.

46. (lv2024thejakstatpathway pages 12-15): You Lv, Jianxun Qi, Jeffrey J. Babon, Longxing Cao, Guohuang Fan, Jiajia Lang, Jin Zhang, Pengbing Mi, Bostjan Kobe, and Faming Wang. The jak-stat pathway: from structural biology to cytokine engineering. Signal Transduction and Targeted Therapy, Aug 2024. URL: https://doi.org/10.1038/s41392-024-01934-w, doi:10.1038/s41392-024-01934-w. This article has 28 citations and is from a peer-reviewed journal.